| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Cash collections from financial royalty assets | 2,438,620 | 1,556,262 | 829,737 | 2,205,933 |
| Cash collections from intangible royalty assets | 681 | 417 | 177 | 14,420 |
| Other royalty cash collections | 84,917 | 55,810 | 31,759 | 79,334 |
| Distributions from equity method investees | 13,396 | 13,396 | 13,396 | 13,396 |
| Interest received | 27,935 | 20,687 | 12,025 | 37,447 |
| Development-stage funding payments | - | 351,000 | 50,500 | 1,500 |
| Development-stage funding payments - upfront and milestone | - | - | - | 0 |
| Development-stage funding payments | 401,500 | - | - | - |
| Payments for operating and professional costs | 229,896 | 195,721 | 101,696 | 163,804 |
| Payments for employee epas | 1,868 | 173 | - | - |
| Interest paid | 269,610 | 139,618 | 138,822 | 158,765 |
| Net cash provided by operating activities | 1,662,675 | 960,060 | 596,076 | 2,026,461 |
| Acquisition of businesses, net of cash acquired | 74,416 | 74,190 | - | - |
| Distributions from equity method investees | 100,155 | 99,250 | 36,262 | 20,397 |
| Investments in equity method investees | 0 | 0 | 0 | 10,955 |
| Purchases of equity securities | 4,427 | 4,427 | 4,427 | 62,500 |
| Proceeds from equity securities | 0 | 0 | - | 98,575 |
| Purchases of available for sale debt securities | 75,000 | 75,000 | - | 150,000 |
| Proceeds from available for sale debt securities | 18,346 | 15,466 | 12,586 | 7,200 |
| Proceeds from sales and maturities of marketable securities | - | - | - | 0 |
| Proceeds from sales of available for sale debt securities | 510,553 | 510,553 | 510,553 | - |
| Acquisitions of financial royalty assets | 964,044 | 2,171 | 1,057 | 2,009,283 |
| Acquisitions of other financial assets | 0 | 0 | - | 18,000 |
| Milestone payments | 268,600 | 268,600 | 50,000 | 50,000 |
| Other | 8,946 | 8,946 | - | -2,039 |
| Net cash used in investing activities | -766,379 | 191,935 | 503,917 | -2,172,527 |
| Distributions to legacy non-controlling interests - portfolio receipts | 275,752 | 173,845 | 84,625 | 281,078 |
| Distributions to continuing non-controlling interests | 126,719 | 92,438 | 53,833 | 93,711 |
| Dividends to shareholders | 283,910 | 188,598 | 95,357 | 282,809 |
| Repurchases of class a ordinary shares | 1,146,846 | 1,000,353 | 708,781 | 177,044 |
| Contributions from legacy non-controlling interests - r&d | 220 | 439 | 220 | 527 |
| Contributions from non-controlling interests - other | 5,697 | 5,682 | 1,077 | 3,329 |
| Proceeds from revolving credit facility | 1,275,000 | - | - | - |
| Repayment of revolving credit facility | 1,275,000 | - | - | - |
| Repayment of long-term debt | 1,000,000 | - | - | 0 |
| Proceeds from issuance of long-term debt, net of discount | 1,954,475 | 0 | - | 1,471,235 |
| Debt issuance costs and other | 13,543 | 0 | - | 12,316 |
| Other | 0 | 0 | - | -9,025 |
| Net cash (used in)/provided by financing activities | -886,378 | -1,449,113 | -941,299 | 619,108 |
| Net change in cash and cash equivalents | 9,918 | -297,118 | 158,694 | 473,042 |
| Cash and cash equivalents at beginning of period | 929,026 | 929,026 | 929,026 | 477,010 |
| Cash and cash equivalents at end of period | 938,944 | 631,908 | 1,087,720 | 950,052 |
Royalty Pharma plc (RPRX)
Royalty Pharma plc (RPRX)